Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI 1820237 + BI 456906
- Development stage
- Phase 1
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules, Peptides
- Administration
- Subcutaneous
01
Overview
BI 1820237 + BI 456906 is an investigational combination of two novel peptide drugs developed for the treatment of overweight and obesity. BI 456906 (also known as survodutide) is a dual agonist at the glucagon-like peptide 1 receptor (GLP-1R) and the glucagon receptor (GCGR), while BI 1820237 is a selective agonist of the neuropeptide Y2 receptor (NPY2R)[4]. Preclinical studies show that BI 1820237 alone causes transient food intake reduction, but its greatest effect appears in combination with BI 456906, where robust and synergistic weight loss is observed above what is possible with either agent alone. The combination is currently under clinical evaluation for its impact on brain activity and body weight regulation in obese/overweight subjects[1][4].
- Other names
- survodutide + BI 1820237
02
Targets
Beyond the preview
Go deeper on BI 1820237 + BI 456906.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI 1820237 + BI 456906.